Prostaglandin F2-alpha (PGF2α) in Vitiligo

Not Applicable

• Conditions: Vitiligo
• Interventions: Other: Skin biopsy

• Registration Number: NCT03755830
• Lead Sponsor: Cairo University

Brief Summary

study the cutaneous expression of PGF2α in vitiligo patients and compare it with normal control subjects.

Detailed Description

Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls.

Study Timeline

• Status Verified: 2018-11
• Study First Submitted: 2018-11-25
• Study First Submitted QC: 2018-11-25
• Last Update Submitted: 2018-11-25
• Study First Posted: 2018-11-28
• Last Update Posted: 2018-11-28
• Study Start: 2018-12
• Primary Completion: 2019-07
• Study Completion: 2019-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patients with non-segmental vitiligo.
• Both sexes.
• Age < 18 years old.
• New cases or cases not receiving any medications for at least 3 months ago.

Read More

Exclusion Criteria

• Age: Patients < 18 years.
• Segmental or universal vitiligo.
• Pregnant and lactating females.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
vitiligo patients	Skin biopsy	Two skin biopsies (lesional and non-lesional) will be taken from every patient.
healthy controls	Skin biopsy	A skin biopsy will be taken from each control subject.

Primary Outcome Measures

Name	Time	Method
Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls.	6 months	Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls to study and verify the hypothesis of involvement of PGF2α in the pathogenesis of vitiligo.• Skin biopsy for assessment of tissue levels of the PGF2α will be taken from both lesional and non lesional skin of patients of vitiligo and from normal skin of healthy controls. All skin biopsies are from non-sun exposed sites.